Objective:

To evaluate the cost implications of implementing point-of-care RNA testing for hepatitis C virus (HCV) in a hospital system.

Approach:

Key Findings:

• Implementing point-of-care RNA testing could increase hospital laboratory costs by up to 260% for the three-hospital system.
• Annual costs for the three-hospital system would rise by approximately $2.9 million, equating to $6,439 per infection detected in that system.

Interpretation:

The high costs associated with point-of-care RNA testing pose significant challenges for healthcare systems, necessitating alternative strategies for HCV testing and treatment, particularly in resource-limited settings.

Limitations:

• Current Medicare reimbursement rates do not reflect the actual costs of point-of-care RNA testing, particularly in the context of the specific healthcare system studied.
• The study's findings are based on a specific healthcare system and may not be generalizable to other settings or populations.

Conclusion:

Targeted deployment strategies and dedicated funding are essential for effective HCV elimination efforts without compromising other laboratory services.

Sources:

• Journal of Clinical Microbiology
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.